LogicBio Therapeutics, Inc. Common Stock
LOGC
LOGC was delisted on the 15th of November, 2022.
39 hedge funds and large institutions have $2.82M invested in LogicBio Therapeutics, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 8 reducing their positions, and 11 closing their positions.
17% less funds holding
Funds holding: 47 → 39 (-8)
27% less capital invested
Capital invested by funds: $3.88M → $2.82M (-$1.06M)
50% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 8
73% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$73.7K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$45.9K |
| 3 |
VF
Virtu Financial
New York
|
+$32K |
| 4 |
Prudential Financial
Newark,
New Jersey
|
+$13.7K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
+$237 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$124K |
| 2 |
Franklin Resources
San Mateo,
California
|
-$109K |
| 3 |
HCA
Harbor Capital Advisors
Chicago,
Illinois
|
-$85K |
| 4 |
Renaissance Technologies
New York
|
-$54.2K |
| 5 |
Jane Street
New York
|
-$18K |
LOGC Hedge Fund Activity: Q3 2022 in Review
39 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in LogicBio Therapeutics, Inc. Common Stock (LOGC) for Q3 2022, worth a combined $2.82M — down 27% from $3.88M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of LOGC and 3 opened new positions — a net loss of 8 holders — while 8 trimmed existing stakes and 4 added.
The largest buyer was Vanguard Group, adding an estimated $73.7K. The largest seller was Baker Bros. Advisors, cutting an estimated $124K.
- 39 institutional investors held LogicBio Therapeutics, Inc. Common Stock (LOGC) as of Q3 2022, down from 47 in Q2 2022.
- Funds reported $2.82M of LogicBio Therapeutics, Inc. Common Stock stock for Q3 2022, down 27% quarter-over-quarter.
- 3 funds opened new LogicBio Therapeutics, Inc. Common Stock positions in Q3 2022 and 11 closed out, a net change of -8 holders.
- The largest LogicBio Therapeutics, Inc. Common Stock buyer in Q3 2022 was Vanguard Group, an estimated $73.7K added.
- The largest LogicBio Therapeutics, Inc. Common Stock seller in Q3 2022 was Baker Bros. Advisors, an estimated $124K sold.
Based on aggregated 13F filings for Q3 2022.